Articles by Faiz Kermani - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Faiz Kermani

Boosting New Antibiotic Drug Development in Europe

With the rising threat of antibiotic resistance and a diminishing R&D pipeline for novel drugs, Europe must step up its game to address this growing problem.
May 2, 2014

With the rising threat of antibiotic resistance and a diminishing R&D pipeline for novel drugs, Europe must step up its game to address this growing problem.

Drug Discovery Partnerships between UK CROs and the Swiss Pharma Sector

The international pharmaceutical industry is changing its approach to R&D and is increasingly relying on outsourcing for drug discovery.
Apr 2, 2014

The international pharmaceutical industry is changing its approach to R&D and is increasingly relying on outsourcing for drug discovery.

Pharma Takes Control Of Distribution Chains

Many pharmaceutical companies in the UK have adopted a direct-to-pharmacy (DTP) distribution model, which enables companies to more tightly control their supply chains. Although DTP has faced some opposition from wholesalers, no legal steps have been taken in the UK to prevent its continued uptake. With the system now beginning to gain a foothold in Poland (although a legal battle with the authorities may ensue), pharma companies may attempt to introduce DTP in other EU countries.
Aug 1, 2010

Many pharmaceutical companies in the UK have adopted a direct-to-pharmacy distribution model, which enables companies to more tightly control their supply chains.

Reducing The Number Of Failures In Early Stage Development

Jul 1, 2010

Phase 0 studies, though not widely accepted, could effectively bridge the gap between preclinical and Phase I studies, and reduce the number of drug failures owing to differences in drug behaviour between animals and humans.

German pharma's hopes and fears

Despite being a historically strong performer in the pharmaceutical arena, Germany is now underperforming compared with the growth of other European markets. Are government cost-containment policies to blame or have German pharmaceutical companies themselves contributed to the decline?
Jun 1, 2010

Despite being a historically strong performer in the pharmaceutical arena, Germany is now underperforming compared with the growth of other European markets.

Change is in the air for the European Clinical Trials Directive

Though many advantages are associated with the European Clinical Trials Directive, complexities have emerged since its introduction in 2004. Since 2007, efforts have been made to raise the issues and address the negative impact of the Directive, and the European Commission is currently assessing stakeholder feedback from a public consultation document, which could lead to changes for the European Clinical Trials Directive.
May 1, 2010

Though many advantages are associated with the European Clinical Trials Directive, complexities have emerged since its introduction in 2004. Since 2007, efforts have been made to raise the issues and address the negative impact of the Directive.

The changing face of European regulatory affairs

Apr 1, 2010

In 1995, pharmaceutical regulation in Europe underwent a dramatic change with the emergence of the European Medicines Agency. The agency's 15-year history has been eventful, with it having to adapt to a changing regulatory landscape and new expectations from those relying on it for guidance.

Reinvigorating European R&D innovation

Mar 1, 2010

Could a collaborative approach involving both public and private parties offer a solution to Europe's lack of innovation?

EU pricing dilemmas

Feb 1, 2010

Although representing a huge market, the EU also presents problems that hamper profitability— particularly when it comes to differing price regulations across member states.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
FindPharma Custom Search
Click here